{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:24:49Z","timestamp":1793759089450,"version":"4.6.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective management of phenylketonuria (PKU) requires consistent blood phenylalanine (Phe) control. However, patients, particularly those with classical PKU, often experience diurnal fluctuations, particularly with early morning Phe levels after an overnight fast. These fluctuations have been linked to neurocognitive and psychological impairments. This 4-week, randomized, controlled crossover study evaluated the efficacy of a prolonged-release amino acid (PR-AA) compared to a conventional free amino acid-based protein substitute (AA) in reducing early morning blood Phe levels in patients with classical PKU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants on a low-Phe diet supplemented with protein substitutes were randomly assigned to one of two treatment arms: Arm A, participants received the PR-AA as a single evening dose for 7\u2009days, followed by a 2-week washout period, then crossed over to receive their usual AA protein substitute for all daily doses for another 7\u2009days. Arm B, the order was reversed. All other daily protein substitute doses remained unchanged, using the patients\u2019 usual Phe-free L-AA protein substitute throughout the study. Blood Phe and tyrosine (Tyr) levels, Phe\/Tyr ratio, branched-chain amino acids (BCAAs), urinary nitrogen and creatinine excretion, tolerability, and patient acceptability were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 16 eligible patients, 13 children with classical PKU (\n                      <jats:italic>n=<\/jats:italic>\n                      8 females, 62%) with a mean age of 11.8\u2009\u00b1\u20093.2\u2009years completed the study. Administration of the PR-AA significantly reduced early morning Phe levels compared to AA (mean difference from baseline to the end of treatment with PR-AA: 63.6\u2009\u00b1\u200928.93\u2009\u00b5mol\/L; \u221217.8%;\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.0484; with AA: 95.5\u2009\u00b1\u200928.9\u2009\u00b5mol\/L; +27.6%;\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.0063). Subgroup analyses indicated greater benefit in patients\u2009&lt;\u200912\u2009years and in those with higher baseline Phe level (&gt;360\u2009\u03bcmol\/L). PR-AA also significantly increased blood Tyr levels, and improved the Phe\/Tyr ratio. No significant differences were observed for other parameters. PR-AA was well tolerated, with high adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PR-AA demonstrated improved metabolic control, particularly in reducing early morning Phe levels. PR-AA may be a useful alternative protein substitute for patients with classical PKU, particularly those with poor metabolic control. Further long-term studies are warranted to assess sustained efficacy, adherence, and neurocognitive outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04264-y","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:18:58Z","timestamp":1775128738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Randomized investigation to evaluate phenylalanine fluctuation after overnight fasting in PKU patients treated with prolonged-release versus standard amino acid protein substitute"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2579-8699","authenticated-orcid":false,"given":"Anne","family":"Daly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Ilgaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ashmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"2","key":"4264_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ajhg.2020.06.006","volume":"107","author":"A Hillert","year":"2020","unstructured":"Hillert A, Anikster Y, Belanger-Quintana A, Burlina A, Burton BK, Carducci C, et al. The genetic Landscape and epidemiology of phenylketonuria. Am J Hum Genet. 2020;107(2):234\u201350. https:\/\/doi.org\/10.1016\/j.ajhg.2020.06.006.","journal-title":"Am J Hum Genet"},{"key":"4264_CR2","doi-asserted-by":"publisher","unstructured":"Blau N, van Spronsen FJ, Lancet Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(10)60961-0.","DOI":"10.1016\/S0140-6736(10)60961-0"},{"issue":"1","key":"4264_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","volume":"7","author":"van Spronsen Fj","year":"2021","unstructured":"van Spronsen Fj, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 2021;7(1):36. https:\/\/doi.org\/10.1038\/s41572-021-00267-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"4264_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(16)30320-5","volume":"5","author":"van Spronsen Fj","year":"2017","unstructured":"van Spronsen Fj, van Wegberg Am, Ahring K, B\u00e9langer-Quintana, Blau N, Bosch AM, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743\u201356. https:\/\/doi.org\/10.1016\/S2213-8587(16)30320-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"4264_CR5","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.3390\/nu14234960","volume":"14","author":"N McWhorter","year":"2022","unstructured":"McWhorter N, Ndugga-Kabuye MK, Puurunen M, Ernst SL. Complications of the low phenylalanine diet for patients with phenylketonuria and the benefits of increased natural protein. Nutrients. 2022;14(23):4960. https:\/\/doi.org\/10.3390\/nu14234960.","journal-title":"Nutrients"},{"issue":"1","key":"4264_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40246-022-00398-9","volume":"16","author":"NA Elhawary","year":"2022","unstructured":"Elhawary NA, AlJahdali IA, Abumansour IS, Elhawary EN, Gaboon N, Dandini M, et al. Genetic etiology and clinical challenges of phenylketonuria. Hum Genomics. 2022;16(1):22. https:\/\/doi.org\/10.1186\/s40246-022-00398-9.","journal-title":"Hum Genomics"},{"issue":"2","key":"4264_CR7","doi-asserted-by":"publisher","first-page":"109125","DOI":"10.1016\/j.ymgme.2025.109125","volume":"145","author":"van Wegberg Amj","year":"2025","unstructured":"van Wegberg Amj, MacDonald A, Ahring K, B\u00e9langer-Quintana, Beblo S, Blau N, et al. European guidelines on diagnosis and treatment of phenylketonuria: first revision. Mol Genet Metab. 2025;145(2):109125. https:\/\/doi.org\/10.1016\/j.ymgme.2025.109125.","journal-title":"Mol Genet Metab"},{"issue":"11","key":"4264_CR8","first-page":"805","volume":"10","author":"J Burnett","year":"2007","unstructured":"Burnett J. Sapropterin Dihydrochloride (Kuvan\/Phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. IDrugs. 2007;10(11):805\u201313. PMID: 17968763.","journal-title":"IDrugs"},{"key":"4264_CR9","doi-asserted-by":"publisher","first-page":"117739281985708","DOI":"10.1177\/1177392819857089","volume":"13","author":"T Hydery","year":"2019","unstructured":"Hydery T, Coppenrath VA. A comprehensive review of Pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria. Drug Target Insights. 2019;13:1177392819857089. https:\/\/doi.org\/10.1177\/1177392819857089.","journal-title":"Drug Target Insights"},{"issue":"1","key":"4264_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-020-01486-6","volume":"15","author":"A MacDonald","year":"2020","unstructured":"MacDonald A, van Wegberg AMJ, Ahring K, Beblo S, B\u00e9langer-Quintana A, Burlina A, et al. PKU dietary handbook to accompany PKU guidelines. Orphanet J Rare Dis. 2020;15(1):230. https:\/\/doi.org\/10.1186\/s13023-020-01486-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"4264_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/14656566.2025.2498477","volume":"26","author":"RA Williams","year":"2025","unstructured":"Williams RA, Bell DA, Hooper AJ, Burnett JR. Sepiapterin for the treatment of phenylketonuria. Expert Opin Pharmacother. 2025;26(8):933\u201338. https:\/\/doi.org\/10.1080\/14656566.2025.2498477.","journal-title":"Expert Opin Pharmacother"},{"key":"4264_CR12","doi-asserted-by":"publisher","unstructured":"Christ SE, Huijbregts SC, de Sonneville LM, White DA. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab. 2010;99(1):S22\u201332. https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.007.","DOI":"10.1016\/j.ymgme.2009.10.007"},{"issue":"1","key":"4264_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-019-1153-y","volume":"14","author":"KF Trefz","year":"2019","unstructured":"Trefz KF, Muntau AC, Kohlscheen KM, Altevers J, Jacob C, Braun S, et al. Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities - a retrospective study of German health insurance claims data. Orphanet J Rare Dis. 2019;14(1):181. https:\/\/doi.org\/10.1186\/s13023-019-1153-y.","journal-title":"Orphanet J Rare Dis"},{"key":"4264_CR14","doi-asserted-by":"publisher","first-page":"104925","DOI":"10.1016\/j.neubiorev.2022.104925","volume":"143","author":"C Romani","year":"2022","unstructured":"Romani C, Olson A, Aitkenhead L, Baker L, Patel D, Spronsen FV, et al. Meta-analyses of cognitive functions in early-treated adults with phenylketonuria. Neurosci Biobehav Rev. 2022;143:104925. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104925.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"4264_CR15","doi-asserted-by":"publisher","first-page":"106969","DOI":"10.1016\/j.ymgme.2022.106969","volume":"138","author":"L Thomas","year":"2023","unstructured":"Thomas L, Olson A, Romani C. The impact of metabolic control on cognition, neurophysiology, and well-being in PKU: a systematic review and meta-analysis of the within-participant literature. Mol Genet Metab. 2023;138(1):106969. https:\/\/doi.org\/10.1016\/j.ymgme.2022.106969.","journal-title":"Mol Genet Metab"},{"issue":"9326","key":"4264_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/s0140-6736(02)09334-0","volume":"360","author":"JH Walter","year":"2002","unstructured":"Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A, et al. How practical are recommendations for dietary control in phenylketonuria? Lancet. 2002;360(9326):55\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(02)09334-0.","journal-title":"Lancet"},{"issue":"2","key":"4264_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/ejcn.2010.258","volume":"65","author":"K Ahring","year":"2011","unstructured":"Ahring K, B\u00e9langer-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, et al. Blood phenylalanine control in phenylketonuria: a survey of 10 European centres. Eur J Clin Nutr. 2011;65(2):275\u201378. https:\/\/doi.org\/10.1038\/ejcn.2010.258.","journal-title":"Eur J Clin Nutr"},{"issue":"3","key":"4264_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","volume":"120","author":"ER Jurecki","year":"2017","unstructured":"Jurecki ER, Cederbaum S, Kopesky J, Perry K, Rohr F, Sanchez-Valle A, et al. Adherence to clinic recommendations among patients with phenylketonuria in the United States. Mol Genet Metab. 2017;120(3):190\u201397. https:\/\/doi.org\/10.1016\/j.ymgme.2017.01.001.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4264_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ymgme.2019.12.007","volume":"129","author":"H Levy","year":"2020","unstructured":"Levy H, Lamppu D, Anastosoaie V, Baker JL, DiBona K, Hawthorne S, et al. 5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics. Mol Genet Metab. 2020;129(3):177\u201385. https:\/\/doi.org\/10.1016\/j.ymgme.2019.12.007.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"4264_CR20","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.3390\/nu13093118","volume":"13","author":"V Kanufre","year":"2021","unstructured":"Kanufre V, Almeida MF, Barbosa CS, Carmona C, Bandeira A, Martins E, et al. Metabolic control of patients with phenylketonuria in a Portuguese metabolic centre comparing three different recommendations. Nutrients. 2021;13(9):3118. https:\/\/doi.org\/10.3390\/nu13093118.","journal-title":"Nutrients"},{"issue":"13","key":"4264_CR21","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.3390\/nu16132064","volume":"16","author":"A Pinto","year":"2024","unstructured":"Pinto A, Ahring K, Almeida MF, Ashmore C, B\u00e9langer-Quintana A, Burlina A, et al. Blood phenylalanine levels in patients with phenylketonuria from Europe between 2012 and 2018: is it a changing Landscape? Nutrients. 2024;16(13):2064. https:\/\/doi.org\/10.3390\/nu16132064.","journal-title":"Nutrients"},{"issue":"2","key":"4264_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/adc.78.2.122","volume":"78","author":"A MacDonald","year":"1998","unstructured":"MacDonald A, Rylance GW, Asplin D, Hall SK, Booth IW. Does a single plasma phenylalanine predict quality of control in phenylketonuria? Arch Dis Child. 1998;78(2):122\u201326. https:\/\/doi.org\/10.1136\/adc.78.2.122.","journal-title":"Arch Dis Child"},{"issue":"5100","key":"4264_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/215512b0","volume":"215","author":"RD Feigin","year":"1967","unstructured":"Feigin RD, Klainer AS, Beisel WR. Circadian periodicity of blood amino-acids in adult men. Nature. 1967;215(5100):512\u201314. https:\/\/doi.org\/10.1038\/215512b0.","journal-title":"Nature"},{"issue":"4","key":"4264_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ymgme.2013.09.001","volume":"110","author":"M Cleary","year":"2013","unstructured":"Cleary M, Trefz F, Muntau AC, Feillet F, van Spronsen FJ, Burlina A, et al. Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes. Mol Genet Metab. 2013;110(4):418\u201323. https:\/\/doi.org\/10.1016\/j.ymgme.2013.09.001.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4264_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1023\/a:1025186217369","volume":"26","author":"A MacDonald","year":"2003","unstructured":"MacDonald A, Rylance G, Davies P, Asplin D, Hall SK, Booth IW. Administration of protein substitute and quality of control in phenylketonuria: a randomized study. J Inherit Metab Dis. 2003;26(4):319\u201326. https:\/\/doi.org\/10.1023\/a:1025186217369.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"4264_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/nu11030520","volume":"11","author":"A Daly","year":"2019","unstructured":"Daly A, Evans S, Chahal S, Santra S, Pinto A, Gingell C, et al. The effect of glycomacropeptide versus amino acids on phenylalanine and tyrosine variability over 24 hours in children with PKU: a randomized controlled trial. Nutrients. 2019;11(3):520. https:\/\/doi.org\/10.3390\/nu11030520.","journal-title":"Nutrients"},{"key":"4264_CR27","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1515\/JPEM-2020-0025","volume":"33","author":"R Ben Abdelaziz","year":"2020","unstructured":"Ben Abdelaziz R, Tangour N, Ben Chehida A, Haj Taieb S, Feki M, Azzouz H, et al. Morning specimen is not representative of metabolic control in Tunisian children with phenylketonuria: a repeated cross-sectional study. J Pediatr Endocrinol Metab. 2020;33:1057\u201364. https:\/\/doi.org\/10.1515\/JPEM-2020-0025.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"4264_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-018-0893-4","volume":"13","author":"DL Hofman","year":"2018","unstructured":"Hofman DL, Champ CL, Lawton CL, Henderson M, Dye L. A systematic review of cognitive functioning in early treated adults with phenylketonuria. Orphanet J Rare Dis. 2018;13(1):150. https:\/\/doi.org\/10.1186\/s13023-018-0893-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4264_CR29","doi-asserted-by":"publisher","first-page":"107684","DOI":"10.1016\/j.ymgme.2023.107684","volume":"140","author":"A De Giorgi","year":"2023","unstructured":"De Giorgi A, Nardecchia F, Romani C, Leuzzi V. Metabolic control and clinical outcome in adolescents with phenylketonuria. Mol Genet Metab. 2023;140(3):107684. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107684.","journal-title":"Mol Genet Metab"},{"key":"4264_CR30","doi-asserted-by":"publisher","unstructured":"Burgard P, Rupp A, Konecki DS, Trefz FK, Schmidt H, Lichter-Konecki U. Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. Eur J Pediatr. 1996;155 Suppl, 1: S11\u20135. https:\/\/doi.org\/10.1007\/pl00014222.","DOI":"10.1007\/pl00014222"},{"issue":"5","key":"4264_CR31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/adc.74.5.412","volume":"74","author":"A MacDonald","year":"1996","unstructured":"MacDonald A, Rylance G, Hall SK, Asplin D, Booth IW. Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. Arch Dis Child. 1996;74(5):412\u201317. https:\/\/doi.org\/10.1136\/adc.74.5.412.","journal-title":"Arch Dis Child"},{"issue":"2\u20133","key":"4264_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ymgme.2010.06.015","volume":"101","author":"BK Burton","year":"2010","unstructured":"Burton BK, Bausell H, Katz R, Laduca H, Sullivan C. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). Mol Genet Metab. 2010;101(2\u20133):110\u201314. https:\/\/doi.org\/10.1016\/j.ymgme.2010.06.015.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"4264_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ymgme.2011.05.011","volume":"104","author":"M Humphrey","year":"2011","unstructured":"Humphrey M, Nation J, Francis I, Boneh A. Effect of tetrahydrobiopterin on Phe\/Tyr ratios and variation in Phe levels in tetrahydrobiopterin responsive PKU patients. Mol Genet Metab. 2011;104(1\u20132):89\u201392. https:\/\/doi.org\/10.1016\/j.ymgme.2011.05.011.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4264_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3390\/ijerph21040431","volume":"21","author":"R Feldmann","year":"2024","unstructured":"Feldmann R, Och U, Beckmann LS, Weglage J, Rutsch F. Children and adolescents with early treated phenylketonuria: cognitive development and fluctuations of blood phenylalanine levels. Int J Environ Res Public Health. 2024;21(4):431. https:\/\/doi.org\/10.3390\/ijerph21040431.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"4264_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1017\/S0954422418000173","volume":"32","author":"A MacDonald","year":"2019","unstructured":"MacDonald A, Singh RH, Rocha JC, van Spronsen FJ. Optimising amino acid absorption: essential to improve nitrogen balance and metabolic control in phenylketonuria. Nutr Res Rev. 2019;32(1):70\u201378. https:\/\/doi.org\/10.1017\/S0954422418000173.","journal-title":"Nutr Res Rev"},{"issue":"2","key":"4264_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1042\/BST20180250","volume":"47","author":"K Javed","year":"2019","unstructured":"Javed K, Fairweather SJ. Amino acid transporters in the regulation of insulin secretion and signalling. Biochem Soc Trans. 2019;47(2):571\u201390. https:\/\/doi.org\/10.1042\/BST20180250.","journal-title":"Biochem Soc Trans"},{"key":"4264_CR37","doi-asserted-by":"publisher","unstructured":"Wolfe RR. Regulation of muscle protein by amino acids. J Nutr. 2002;132(10):3219S\u201324. https:\/\/doi.org\/10.1093\/jn\/131.10.3219S.","DOI":"10.1093\/jn\/131.10.3219S"},{"issue":"8","key":"4264_CR38","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.3390\/nu12082457","volume":"12","author":"JA Gwin","year":"2020","unstructured":"Gwin JA, Church DD, Wolfe RR, Ferrando AA, Pasiakos SM. Muscle protein synthesis and whole-body protein turnover responses to ingesting essential amino acids, intact protein, and protein-containing mixed meals with considerations for energy deficit. Nutrients. 2020;12(8):2457. https:\/\/doi.org\/10.3390\/nu12082457.","journal-title":"Nutrients"},{"issue":"1","key":"4264_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/014860719101500148","volume":"15","author":"SS Gropper","year":"1991","unstructured":"Gropper SS, Acosta PB. Effect of simultaneous ingestion of L-amino acids and whole protein on plasma amino acid and urea nitrogen concentrations in humans. JPEN J Parenter Enter Nutr. 1991;15(1):48\u201353. https:\/\/doi.org\/10.1177\/014860719101500148.","journal-title":"JPEN J Parenter Enter Nutr"},{"key":"4264_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/PL00014226","volume":"155","author":"E M\u00f6nch","year":"1996","unstructured":"M\u00f6nch E. Utilisation of amino acid mixtures in adolescents with phenylketonuria. Eur J Pediatr. 1996;155 Suppl, 1: 115\u201320. https:\/\/doi.org\/10.1007\/PL00014226.","journal-title":"Eur J Pediatr"},{"key":"4264_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2326409818783780","volume":"6","author":"N Giarratana","year":"2018","unstructured":"Giarratana N, Gallina G, Panzeri V, Frangi A, Canobbio A, Reiner G. A New Phe-free protein substitute engineered to allow a physiological absorption of free amino acids for phenylketonuria. J Inborn Errors Metab Screen. 2018;6:1\u20139. https:\/\/doi.org\/10.1177\/2326409818783780.","journal-title":"J Inborn Errors Metab Screen"},{"issue":"4","key":"4264_CR42","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/ijms23042227","volume":"23","author":"N Giarratana","year":"2022","unstructured":"Giarratana N, Giardino L, Bighinati A, Reiner G, Rocha JC. In vivo metabolic responses to different formulations of amino acid mixtures for the treatment of phenylketonuria (PKU). Int J Mol Sci. 2022;23(4):2227. https:\/\/doi.org\/10.3390\/ijms23042227.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4264_CR43","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3390\/nu13093189","volume":"13","author":"M Scheinin","year":"2021","unstructured":"Scheinin M, Junnila J, Reiner G, MacDonald A, Muntau AC. Nitrogen balance after the administration of a prolonged-release protein substitute for phenylketonuria as a single dose in healthy volunteers. Nutrients. 2021;13(9):3189. https:\/\/doi.org\/10.3390\/nu13093189.","journal-title":"Nutrients"},{"issue":"6","key":"4264_CR44","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3390\/nu12061653","volume":"12","author":"M Scheinin","year":"2020","unstructured":"Scheinin M, Barassi A, Junnila J, Lovr\u00f3 Z, Reiner G, Sarkkinen E, et al. Amino acid plasma profiles from a prolonged-release protein substitute for phenylketonuria: a randomized, single-dose, four-way crossover trial in healthy Volunteers. Nutrients. 2020;12(6):1653. https:\/\/doi.org\/10.3390\/nu12061653.","journal-title":"Nutrients"},{"issue":"9","key":"4264_CR45","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.3390\/nu12092686","volume":"12","author":"A MacDonald","year":"2020","unstructured":"MacDonald A, Ashmore C, Daly A, Pinto A, Evans S. An observational study evaluating the introduction of a prolonged-release protein substitute to the dietary management of children with phenylketonuria. Nutrients. 2020;12(9):2686. https:\/\/doi.org\/10.3390\/nu12092686.","journal-title":"Nutrients"},{"issue":"2","key":"4264_CR46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/02601060241248522","volume":"31","author":"S Sestito","year":"2025","unstructured":"Sestito S, Brodosi L, Ferraro S, Carella R, De Giovanni D, Mita D, et al. Benefits of a prolonged-release amino acid mixture in four pregnant women with phenylketonuria. Nutr Health. 2025;31(2):777\u201388. https:\/\/doi.org\/10.1177\/02601060241248522.","journal-title":"Nutr Health"},{"issue":"1","key":"4264_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/02601060231184934","volume":"30","author":"C Newby","year":"2024","unstructured":"Newby C. Introducing a granule based protein substitute to the diet of a Child with phenylketonuria to address reluctance to ingest phenylalanine-free protein substitute: a case report. Nutr Health. 2024;30(1):35\u201338. https:\/\/doi.org\/10.1177\/02601060231184934.","journal-title":"Nutr Health"},{"key":"4264_CR48","unstructured":"Blau NB Available online: http:\/\/www.biopku.org\/home\/home.asp. accessed on 23 Aug 2025."},{"issue":"1","key":"4264_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/jama.2014.7523","volume":"312","author":"MA Detry","year":"2014","unstructured":"Detry MA, Lewis RJ. The intention-to-treat principle: how to assess the true effect of choosing a medical treatment. JAMA. 2014;312(1):85\u201386. https:\/\/doi.org\/10.1001\/jama.2014.7523.","journal-title":"JAMA"},{"issue":"5","key":"4264_CR50","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.2021.2825","volume":"326","author":"VA Smith","year":"2021","unstructured":"Smith VA, Coffman CJ, Hudgens MG. Interpreting the results of intention-to-treat, per-protocol, and As-treated analyses of clinical trials. JAMA. 2021;326(5):433\u201334. https:\/\/doi.org\/10.1001\/jama.2021.2825.","journal-title":"JAMA"},{"issue":"1","key":"4264_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2307\/2529321","volume":"33","author":"S Wallenstein","year":"1977","unstructured":"Wallenstein S, Fisher AC. The analysis of the two-period repeated measurements crossover design with application to clinical trials. Biometrics. 1977;33(1):261\u201369. https:\/\/doi.org\/10.2307\/2529321.","journal-title":"Biometrics"},{"key":"4264_CR52","doi-asserted-by":"publisher","unstructured":"Hopewell S, Chan AW, Collins GS, Hr\u00f3bjartsson A, Moher D, Schulz KF, et al. CONSORT, 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. https:\/\/doi.org\/10.1136\/bmj-2024-081123.","DOI":"10.1136\/bmj-2024-081123"},{"issue":"4","key":"4264_CR53","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ymgme.2014.01.012","volume":"111","author":"A Hood","year":"2014","unstructured":"Hood A, Grange DK, Christ SE, Steiner R, White DA. Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria. Mol Genet Metab. 2014;111(4):445\u201351. https:\/\/doi.org\/10.1016\/j.ymgme.2014.01.012.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4264_CR54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13023-019-1225-z","volume":"14","author":"C Romani","year":"2019","unstructured":"Romani C, Manti F, Nardecchia F, Valentini F, Fallarino N, Carducci C, et al. Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels. Orphanet J Rare Dis. 2019;14(1):273. https:\/\/doi.org\/10.1186\/s13023-019-1225-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4264_CR55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/ajcn\/24.3.329","volume":"24","author":"RD Feigin","year":"1971","unstructured":"Feigin RD, Beisel WR, Wannemacher RW Jr. Rhythmicity of plasma amino acids and relation to dietary intake. Am J Clin Nutr. 1971;24(3):329\u201341. https:\/\/doi.org\/10.1093\/ajcn\/24.3.329.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"4264_CR56","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF00805988","volume":"5","author":"J Demling","year":"1993","unstructured":"Demling J, Langer K, W\u00f6rthm\u00fcller M, Yusufu V. Individual day-to-day variations in plasma amino acid levels in healthy persons. Amino Acids. 1993;5(2):253\u201362. https:\/\/doi.org\/10.1007\/BF00805988.","journal-title":"Amino Acids"},{"issue":"20","key":"4264_CR57","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.3390\/nu14204268","volume":"14","author":"A Pinto","year":"2022","unstructured":"Pinto A, Daly A, Rocha JC, Ashmore C, Evans S, Jackson R, et al. Impact of fruit and vegetable protein vs. Milk protein on metabolic control of children with phenylketonuria: a randomized crossover controlled trial. Nutrients. 2022;14(20):4268. https:\/\/doi.org\/10.3390\/nu14204268.","journal-title":"Nutrients"},{"key":"4264_CR58","doi-asserted-by":"publisher","unstructured":"Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev. 1997;62(4):i-v, 1\u2013208. https:\/\/doi.org\/10.2307\/1166208.","DOI":"10.2307\/1166208"},{"issue":"6","key":"4264_CR59","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/1467-8624.00370","volume":"72","author":"M Luciana","year":"2001","unstructured":"Luciana M, Sullivan J, Nelson CA. Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev. 2001;72(6):1637\u201352. https:\/\/doi.org\/10.1111\/1467-8624.00370.","journal-title":"Child Dev"},{"issue":"1","key":"4264_CR60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/87565640903325725","volume":"35","author":"R Sharman","year":"2010","unstructured":"Sharman R, Sullivan K, Young R, McGill J. A preliminary investigation of the role of the phenylalanine: tyrosine ratio in children with early and continuously treated phenylketonuria: toward identification of \u201csafe\u201d levels. Dev Neuropsychol. 2010;35(1):57\u201365. https:\/\/doi.org\/10.1080\/87565640903325725.","journal-title":"Dev Neuropsychol"},{"issue":"4","key":"4264_CR61","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1542\/peds.92.4.570","volume":"92","author":"van Spronsen Fj","year":"1993","unstructured":"van Spronsen FJ, van Rijn M, van Dijk T, Smit GP, Reijngoud DJ, Berger R, et al. Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting\/postprandial) in patients with phenylketonuria: effect of sample timing. Pediatrics. 1993;92(4):570\u201373. PMID: 8414829.","journal-title":"Pediatrics"},{"issue":"7","key":"4264_CR62","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/BF01957005","volume":"153","author":"ME Herrmann","year":"1994","unstructured":"Herrmann ME, Br\u00f6sicke HG, Keller M, M\u00f6nch E, Helge H. Dependence of the utilization of a phenylalanine-free amino acid mixture on different amounts of single dose ingested. A case report. Eur J Pediatr. 1994;153(7):501\u201303. https:\/\/doi.org\/10.1007\/BF01957005.","journal-title":"Eur J Pediatr"},{"key":"4264_CR63","doi-asserted-by":"publisher","unstructured":"de Groot Mj, Hoeksma M, Blau N, Reijngoud DJ, van Spronsen Fj. Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab. 2010;99Suppl, 1):S86\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.016.","DOI":"10.1016\/j.ymgme.2009.10.016"},{"key":"4264_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1750-1172-8-133","volume":"8","author":"de Groot Mj","year":"2013","unstructured":"de Groot Mj, Hoeksma M, Reijngoud DJ, de Valk Hw, Paans AM, Sauer PJ, et al. Phenylketonuria: reduced tyrosine brain influx relates to reduced cerebral protein synthesis. Orphanet J Rare Dis. 2013;8:133. https:\/\/doi.org\/10.1186\/1750-1172-8-133.","journal-title":"Orphanet J Rare Dis"},{"issue":"4059","key":"4264_CR65","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1126\/science.178.4059.414","volume":"178","author":"JD Fernstrom","year":"1972","unstructured":"Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological regulation by plasma neutral amino acids. Science. 1972;178(4059):414\u201316. https:\/\/doi.org\/10.1126\/science.178.4059.414.","journal-title":"Science"},{"issue":"3","key":"4264_CR66","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1046\/j.1471-4159.1995.64031252.x","volume":"64","author":"BL Shulkin","year":"1995","unstructured":"Shulkin BL, Betz AL, Koeppe RA, Agranoff BW. Inhibition of neutral amino acid transport across the human blood-brain barrier by phenylalanine. J Neurochem. 1995;64(3):1252\u201357. https:\/\/doi.org\/10.1046\/j.1471-4159.1995.64031252.x.","journal-title":"J Neurochem"},{"issue":"6","key":"4264_CR67","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/BF02436753","volume":"18","author":"GM Knudsen","year":"1995","unstructured":"Knudsen GM, Hasselbalch S, Toft PB, Christensen E, Paulson OB, Lou H. Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. J Inherit Metab Dis. 1995;18(6):653\u201364. https:\/\/doi.org\/10.1007\/BF02436753.","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"4264_CR68","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1097\/00004647-199811000-00004","volume":"18","author":"HE M\u00f6ller","year":"1998","unstructured":"M\u00f6ller HE, Weglage J, Wiedermann D, Ullrich K. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab. 1998;18(11):1184\u201391. https:\/\/doi.org\/10.1097\/00004647-199811000-00004.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"4264_CR69","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ymgme.2008.12.019","volume":"96","author":"M Hoeksma","year":"2009","unstructured":"Hoeksma M, Reijngoud DJ, Pruim J, de Valk HW, Paans AM, van Spronsen FJ. Phenylketonuria: high plasma phenylalanine decreases cerebral protein synthesis. Mol Genet Metab. 2009;96(4):177\u201382. https:\/\/doi.org\/10.1016\/j.ymgme.2008.12.019.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"4264_CR70","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/08035259850158308","volume":"87","author":"GL Arnold","year":"1998","unstructured":"Arnold GL, Kramer BM, Kirby RS, Plumeau PB, Blakely EM, Sanger Cregan LS, et al. Factors affecting cognitive, motor, behavioral and executive functioning in children with phenylketonuria. Acta Paediatr. 1998, May;87(5):565\u201370. https:\/\/doi.org\/10.1080\/08035259850158308.","journal-title":"Acta Paediatr"},{"issue":"2","key":"4264_CR71","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.gene.2012.05.007","volume":"504","author":"R Sharman","year":"2012","unstructured":"Sharman R, Sullivan K, Young RM, McGill J. Depressive symptoms in adolescents with early and continuously treated phenylketonuria: associations with phenylalanine and tyrosine levels. Gene. 2012;504(2):288\u201391. https:\/\/doi.org\/10.1016\/j.gene.2012.05.007.","journal-title":"Gene"},{"issue":"1","key":"4264_CR72","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3305\/NH.2010.25.1.4482","volume":"25","author":"MA Vilaseca","year":"2010","unstructured":"Vilaseca MA, Lambruschini N, G\u00f3mez-L\u00f3pez L, Guti\u00e9rrez A, Fust\u00e9 E, Gassi\u00f3 R, et al. Quality of dietary control in phenylketonuric patients and its relationship with general intelligence. Nutr Hosp. 2010;25(1):60\u201366. https:\/\/doi.org\/10.3305\/NH.2010.25.1.4482.","journal-title":"Nutr Hosp"},{"issue":"1","key":"4264_CR73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2014.11.007","volume":"114","author":"A Hood","year":"2015","unstructured":"Hood A, Antenor-Dorsey JA, Rutlin J, Hershey T, Shimony JS, McKinstry RC, et al. Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria. Mol Genet Metab. 2015;114(1):19\u201324. https:\/\/doi.org\/10.1016\/j.ymgme.2014.11.007.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4264_CR74","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1037\/neu0000336","volume":"31","author":"C Romani","year":"2017","unstructured":"Romani C, Palermo L, MacDonald A, Limback E, Hall SK, Geberhiwot T. The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: effects across tasks and developmental stages. Neuropsychology. 2017;31(3):242\u201354. https:\/\/doi.org\/10.1037\/neu0000336.","journal-title":"Neuropsychology"},{"issue":"3","key":"4264_CR75","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/apa.14517","volume":"108","author":"R Feldmann","year":"2019","unstructured":"Feldmann R, Schallert M, Nguyen T, Och U, Rutsch F, Weglage J. Children and adolescents with phenylketonuria display fluctuations in their blood phenylalanine levels. Acta Paediatr. 2019;108(3):541\u201343. https:\/\/doi.org\/10.1111\/apa.14517.","journal-title":"Acta Paediatr"},{"issue":"4","key":"4264_CR76","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s10545-011-9329-1","volume":"34","author":"KS Viau","year":"2011","unstructured":"Viau KS, Wengreen HJ, Ernst SL, Cantor NL, Furtado LV, Longo N. Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria. J Inherit Metab Dis. 2011;34(4):963\u201371. https:\/\/doi.org\/10.1007\/s10545-011-9329-1.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"4264_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ymgme.2008.06.014","volume":"95","author":"V Anastasoaie","year":"2008","unstructured":"Anastasoaie V, Kurzius L, Forbes P, Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol Genet Metab. 2008;95(1\u20132):17\u201320. https:\/\/doi.org\/10.1016\/j.ymgme.2008.06.014.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"4264_CR78","doi-asserted-by":"publisher","first-page":"527","DOI":"10.18388\/abp.2017_1524","volume":"64","author":"B Didycz","year":"2017","unstructured":"Didycz B, Bik-Multanowski M. Dynamics of hyperphenylalaninemia and intellectual outcome in teenagers with phenylketonuria. Acta Biochim Pol. 2017;64(3):527\u201331. https:\/\/doi.org\/10.18388\/abp.2017_1524.","journal-title":"Acta Biochim Pol"},{"key":"4264_CR79","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ymgmr.2017.12.003","volume":"14","author":"B Didycz","year":"2017","unstructured":"Didycz B, Bik-Multanowski M. Blood phenylalanine instability strongly correlates with anxiety in phenylketonuria. Mol Genet Metab Rep. 2017;14:80\u201382. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.12.003.","journal-title":"Mol Genet Metab Rep"},{"issue":"10","key":"4264_CR80","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.3390\/nu12103033","volume":"12","author":"C Romani","year":"2020","unstructured":"Romani C, Manti F, Nardecchia F, Valentini F, Fallarino N, Carducci C, et al. Cognitive outcomes and relationships with phenylalanine in phenylketonuria: a comparison between Italian and English adult samples. Nutrients. 2020;12(10):3033. https:\/\/doi.org\/10.3390\/nu12103033.","journal-title":"Nutrients"},{"issue":"2","key":"4264_CR81","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/10815589221143485","volume":"71","author":"C Costa-Lathan","year":"2023","unstructured":"Costa-Lathan C, Vazquez-Agra N, Marques-Afonso AT, Cruces-Sande A, Martinez-Olmos MA, Araujo-Vilar D, et al. The role of phenylalanine levels in the neuropsychological and neuroanatomical status of adult patients with phenylketonuria: the impact of fluctuations. J Investig Med. 2023;71(2):149\u201358. https:\/\/doi.org\/10.1177\/10815589221143485.","journal-title":"J Investig Med"},{"issue":"4","key":"4264_CR82","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000342256","volume":"61","author":"A MacDonald","year":"2012","unstructured":"MacDonald A, van Rijn M, Feillet F, Lund AM, Bernstein L, Bosch AM, et al. Adherence issues in inherited metabolic disorders treated by low natural protein diets. Ann Nutr Metab. 2012;61(4):289\u201395. https:\/\/doi.org\/10.1159\/000342256.","journal-title":"Ann Nutr Metab"},{"key":"4264_CR83","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgmr.2018.10.002","volume":"17","author":"S Ford","year":"2018","unstructured":"Ford S, O\u2019Driscoll M, MacDonald A. Living with phenylketonuria: lessons from the PKU community. Mol Genet Metab Rep. 2018;17:57\u201363. https:\/\/doi.org\/10.1016\/j.ymgmr.2018.10.002.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"4264_CR84","doi-asserted-by":"publisher","first-page":"108120","DOI":"10.1016\/j.ymgme.2023.108120","volume":"141","author":"K Ahring","year":"2024","unstructured":"Ahring K, B\u00e9langer-Quintana A, Burlina A, Gi\u017cewska M, Maillot F, Muntau A, et al. Management of phenylketonuria in European PKU centres remains heterogeneous. Mol Genet Metab. 2024;141(1):108120. https:\/\/doi.org\/10.1016\/j.ymgme.2023.108120.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4264_CR85","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/nu13020484","volume":"13","author":"A Daly","year":"2021","unstructured":"Daly A, Evans S, Pinto A, Ashmore C, MacDonald A. Protein substitutes in PKU; their historical evolution. Nutrients. 2021;13(2):484. https:\/\/doi.org\/10.3390\/nu13020484.","journal-title":"Nutrients"},{"issue":"6","key":"4264_CR86","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1073\/pnas.96.6.3160.Erratum","volume":"96","author":"S Kaufman","year":"1999","unstructured":"Kaufman S. A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients. Proc Natl Acad Sci USA. 1999;96(6):3160\u201364. https:\/\/doi.org\/10.1073\/pnas.96.6.3160.Erratum.","journal-title":"Proc Natl Acad Sci USA"}],"updated-by":[{"DOI":"10.1186\/s13023-026-04386-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04264-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04264-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04264-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:36:20Z","timestamp":1785504980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04264-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4264"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04264-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13023-026-04386-3","URL":"https:\/\/doi.org\/10.1186\/s13023-026-04386-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was given by the North West - Greater Manchester West Research Ethics Committee on 30 April 2022. The Health Research Authority and Health and Care Research Wales Approval Letter was issued on 03 May 2022. Written informed consent was obtained from each participant or by the participant\u2019s legally acceptable representative prior to evaluations performed for eligibility. The study was conducted in accordance with International Conference on Harmonization Good Clinical Practice (ICH GCP E6 R2) and applicable laws and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No individual identifying data is included. Participant consent forms included a statement confirming consent for the use of anonymized quotes.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.M. is an advisory board member for ELEMENT Danone-Nutricia, Arla, Applied Pharma Research, Vitaflo International and PTC pharmaceuticals, and has received research funding and honoraria from Nutricia, Vitaflo International, MetaHealth, Galen, Arla, and Metax. S.E. has received financial support and honoraria from Nutricia and Vitaflo International to attend\/speak at study days and conferences. A.P. has received an educational grant from Cambrooke Therapeutics, research funding from Vitaflo, Nutricia, and Biomarin. Biomarin, Mevalia, Vitaflo and Nutricia have provided research funding to attend scientific meetings. F.I. has received a small honorarium from Applied Pharma Research as compensation for time spent on drafting and writing the manuscript, and honoraria from Vitaflo to attend conferences. C.A., and A.D. declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"127"}}